Read More

Vaxcyte Exercises Option And Enters Into Manufacturing Rights Agreement With Sutro Biopharma To Obtain Control Over Manufacturing And Development Of Cell-Free Extract For Its Vaccine Candidates

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company's Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement

PCVX

Read More

Xenon Pharma’s Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst

Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe 

XENE

Read More

Janssen Submits Application To The European Medicines Agency For RYBREVANT In Combination With Chemotherapy For The Treatment Of Adult Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure Of Prior Therapy

https://www.janssen.com/janssen-submits-application-european-medicines-agency-rybrevantrv-amivantamab-combinationThe submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking

JNJ